The Medicines Company to Hold Conference Call on Tuesday, June 2 to Discuss Clinical Trial Results of ABP-700 and MDCO-216
The Medicines Company (NASDAQ: MDCO) has scheduled a conference call on June 2 at 8:30am EST to discuss results of first phase clinical studies for the investigational anesthetic agent, ABP-700, and the investigational lipid-modulating agent, MDCO-216. Summary results for ABP-700 were presented at the Dutch Society of Anesthesiology in Maastricht, Netherlands, while results for MDCO-216 were presented at the 17th International Symposium on Atherosclerosis in Amsterdam, Netherlands.
The conference call will be available via phone and webcast. The dial-in information is listed below:
Domestic Dial In: + 1 (877) 359-9508
International Dial In: + 1 (224) 357-2393
Passcode for both dial-in numbers: 58742775
Replay is available from 11:30 a.m. Eastern Time following the conference call through June 9, 2015. To hear a replay of the call, dial +1 (855) 859-2056 (domestic) and +1 (404) 537-3406 (international). Passcode for both dial in numbers is 58742775.
This call is being webcast and can be accessed via The Medicines Company website at www.themedicinescompany.com.
About The Medicines Company
The Medicines Company's purpose is to save lives, alleviate suffering and contribute to the economics of healthcare by focusing on 3000 leading acute/intensive care hospitals worldwide. Its vision is to be a leading provider of solutions in three areas: serious infectious disease care, acute cardiovascular care and surgery and perioperative care. The company operates in the Americas, Europe and the Middle East, and Asia Pacific regions with global centers today in Parsippany, NJ, USA and Zurich, Switzerland.
The Medicines Company
Neera Dahiya Ravindran, MD, +1 973-290-6044
Vice President, Investor Relations & Strategic Planning
Bob Laverty, +1 973-290-6162
Mobile +1 609-558-5570
Vice President, Communications